{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:59:32Z","timestamp":1791280772409,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The increasing availability of different monoclonal antibodies (mAbs) opens the way to more specific biologic therapy of cancer patients. However, despite the significant success of therapy in breast and ovarian carcinomas with anti-HER2 mAbs as well as in non-Hodkin B cell lymphomas with anti-CD20 mAbs, certain B cell malignancies such as B chronic lymphocytic leukaemia (B-CLL) respond poorly to anti-CD20 mAb, due to the low surface expression of this molecule. Thus, new mAbs adapted to each types of tumour will help to develop personalised mAb treatment. To this aim, we analyse the biological and therapeutic properties of three mAbs directed against the CD5, CD71 or HLA-DR molecules highly expressed on B-CLL cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The three mAbs, after purification and radiolabelling demonstrated high and specific binding capacity to various human leukaemia target cells. Further<jats:italic>in vitro<\/jats:italic>analysis showed that mAb anti-CD5 induced neither growth inhibition nor apoptosis, mAb anti-CD71 induced proliferation inhibition with no early sign of cell death and mAb anti-HLA-DR induced specific cell aggregation, but without evidence of apoptosis. All three mAbs induced various degrees of ADCC by NK cells, as well as phagocytosis by macrophages. Only the anti-HLA-DR mAb induced complement mediated lysis. Coincubation of different pairs of mAbs did not significantly modify the in vitro results. In contrast with these discrete and heterogeneous<jats:italic>in vitro<\/jats:italic>effects,<jats:italic>in vivo<\/jats:italic>the three mAbs demonstrated marked anti-tumour efficacy and prolongation of mice survival in two models of SCID mice, grafted either intraperitoneally or intravenously with the CD5 transfected JOK1-5.3 cells. This cell line was derived from a human hairy cell leukaemia, a type of malignancy known to have very similar biological properties as the B-CLL, whose cells constitutively express CD5. Interestingly, the combined injection of anti-CD5 with anti-HLA-DR or with anti-CD71 led to longer mouse survival, as compared to single mAb injection, up to complete inhibition of tumour growth in 100% mice treated with both anti-HLA-DR and anti-CD5.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Altogether these data suggest that the combined use of two mAbs, such as anti-HLA-DR and anti-CD5, may significantly enhance their therapeutic potential.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1476-4598-10-42","type":"journal-article","created":{"date-parts":[[2011,4,23]],"date-time":"2011-04-23T06:17:17Z","timestamp":1303539437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia"],"prefix":"10.1186","volume":"10","author":[{"given":"S\u00e9verine","family":"Loisel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Alain","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josee","family":"Golay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Buchegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Kadouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"C\u00e9rutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bologna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Kosinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Viertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika Bischof","family":"Delaloye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Berthou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Boumsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,19]]},"reference":[{"key":"878_CR1","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/eji.1830081214","volume":"8","author":"L Boumsell","year":"1978","unstructured":"Boumsell L, Bernard A, Lepage V, Degos L, Lemerle J, Dausset J: Some chronic lymphocytic leukemia cells bearing surface immunoglobulins share determinants with T cells. Eur J Immunol. 1978, 8: 900-904.","journal-title":"Eur J Immunol"},{"key":"878_CR2","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1182\/blood.V99.11.4087","volume":"99","author":"RN Damle","year":"2002","unstructured":"Damle RN, Ghiotto F, Valetto A, Albesiano E, Fais F, Yan XJ, Sison CP, Allen SL, Kolitz J, Schulman P: B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood. 2002, 99: 4087-4093.","journal-title":"Blood"},{"key":"878_CR3","doi-asserted-by":"publisher","first-page":"6821","DOI":"10.4049\/jimmunol.178.11.6821","volume":"178","author":"G Friedlein","year":"2007","unstructured":"Friedlein G, El Hage F, Vergnon I, Richon C, Saulnier P, Lecluse Y, Caignard A, Boumsell L, Bismuth G, Chouaib S, Mami-Chouaib F: Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death. J Immunol. 2007, 178: 6821-6827.","journal-title":"J Immunol"},{"key":"878_CR4","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1182\/blood-2002-05-1525","volume":"100","author":"H Gary-Gouy","year":"2002","unstructured":"Gary-Gouy H, Harriague J, Bismuth G, Platzer C, Schmitt C, Dalloul AH: Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood. 2002, 100: 4537-4543.","journal-title":"Blood"},{"key":"878_CR5","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.1984.2.8.881","volume":"2","author":"RO Dillman","year":"1984","unstructured":"Dillman RO, Shawler DL, Dillman JB, Royston I: Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol. 1984, 2: 881-891.","journal-title":"J Clin Oncol"},{"key":"878_CR6","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood.V62.5.988.988","volume":"62","author":"RA Miller","year":"1983","unstructured":"Miller RA, Oseroff AR, Stratte PT, Levy R: Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood. 1983, 62: 988-995.","journal-title":"Blood"},{"key":"878_CR7","first-page":"97","volume":"7","author":"AA Hertler","year":"1988","unstructured":"Hertler AA, Schlossman DM, Borowitz MJ, Laurent G, Jansen FK, Schmidt C, Frankel AE: A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. J Biol Response Mod. 1988, 7: 97-113.","journal-title":"J Biol Response Mod"},{"key":"878_CR8","first-page":"2691","volume":"4","author":"FM Foss","year":"1998","unstructured":"Foss FM, Raubitscheck A, Mulshine JL, Fleisher TA, Reynolds JC, Paik CH, Neumann RD, Boland C, Perentesis P, Brown MR: Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res. 1998, 4: 2691-2700.","journal-title":"Clin Cancer Res"},{"key":"878_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/sj.leu.2402393","volume":"16","author":"DP Cioca","year":"2002","unstructured":"Cioca DP, Kitano K: Apoptosis induction by hypercross-linking of the surface antigen CD5 with anti-CD5 monoclonal antibodies in B cell chronic lymphocytic leukemia. Leukemia. 2002, 16: 335-343.","journal-title":"Leukemia"},{"key":"878_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/sj.leu.2402327","volume":"16","author":"JO Pers","year":"2002","unstructured":"Pers JO, Berthou C, Porakishvili N, Burdjanadze M, Le Calvez G, Abgrall JF, Lydyard PM, Youinou P, Jamin C: CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia. Leukemia. 2002, 16: 44-52.","journal-title":"Leukemia"},{"key":"878_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.clim.2006.06.010","volume":"121","author":"TR Daniels","year":"2006","unstructured":"Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML: The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006, 121: 144-158.","journal-title":"Clin Immunol"},{"key":"878_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1136\/jcp.36.5.539","volume":"36","author":"KC Gatter","year":"1983","unstructured":"Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY: Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol. 1983, 36: 539-545.","journal-title":"J Clin Pathol"},{"key":"878_CR13","first-page":"37","volume":"4","author":"A Das Gupta","year":"1990","unstructured":"Das Gupta A, Shah VI: Correlation of transferrin receptor expression with histologic grade and immunophenotype in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Hematol Pathol. 1990, 4: 37-41.","journal-title":"Hematol Pathol"},{"key":"878_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/ijc.2910320314","volume":"32","author":"R Taetle","year":"1983","unstructured":"Taetle R, Honeysett JM, Trowbridge I: Effects of anti-transferrin receptor antibodies on growth of normal and malignant myeloid cells. Int J Cancer. 1983, 32: 343-349.","journal-title":"Int J Cancer"},{"key":"878_CR15","first-page":"1259","volume":"1","author":"D Brooks","year":"1995","unstructured":"Brooks D, Taylor C, Dos Santos B, Linden H, Houghton A, Hecht TT, Kornfeld S, Taetle R: Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42\/6. Clin Cancer Res. 1995, 1: 1259-1265.","journal-title":"Clin Cancer Res"},{"key":"878_CR16","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00262-005-0105-7","volume":"55","author":"Y Qing","year":"2006","unstructured":"Qing Y, Shuo W, Zhihua W, Huifen Z, Ping L, Lijiang L, Xiaorong Z, Liming C, Daiwen X, Yu H: The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor. Cancer Immunol Immunother. 2006, 55: 1111-1121.","journal-title":"Cancer Immunol Immunother"},{"key":"878_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0092-8674(84)90068-0","volume":"36","author":"JF Kaufman","year":"1984","unstructured":"Kaufman JF, Auffray C, Korman AJ, Shackelford DA, Strominger J: The class II molecules of the human and murine major histocompatibility complex. Cell. 1984, 36: 1-13.","journal-title":"Cell"},{"key":"878_CR18","doi-asserted-by":"publisher","first-page":"10459","DOI":"10.1073\/pnas.90.22.10459","volume":"90","author":"MK Newell","year":"1993","unstructured":"Newell MK, VanderWall J, Beard KS, Freed JH: Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes. Proc Natl Acad Sci USA. 1993, 90: 10459-10463.","journal-title":"Proc Natl Acad Sci USA"},{"key":"878_CR19","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/eji.1830250811","volume":"25","author":"T Yoshino","year":"1995","unstructured":"Yoshino T, Cao L, Nishiuchi R, Matsuo Y, Yamadori I, Kondo E, Teramoto N, Hayashi K, Takahashi K, Kamikawaji N: Ligation of HLA class II molecules promotes sensitivity to CD95 (Fas antigen, APO-1)-mediated apoptosis. Eur J Immunol. 1995, 25: 2190-2194.","journal-title":"Eur J Immunol"},{"key":"878_CR20","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1182\/blood-2010-06-289736","volume":"116","author":"J Golay","year":"2010","unstructured":"Golay J, Bologna L, Andr\u00e9 PA, Buchegger F, Mach JP, Boumsell L, Introna M: Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death. Blood. 2010, 116: 3372-3.","journal-title":"Blood"},{"key":"878_CR21","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2706::AID-CNCR49>3.0.CO;2-D","volume":"80","author":"GL DeNardo","year":"1997","unstructured":"DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ: Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer. 1997, 80: 2706-2711.","journal-title":"Cancer"},{"key":"878_CR22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3816\/CLM.2001.n.026","volume":"2","author":"KS Brown","year":"2001","unstructured":"Brown KS, Levitt DJ, Shannon M, Link BK: Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma. Clin Lymphoma. 2001, 2: 188-190.","journal-title":"Clin Lymphoma"},{"key":"878_CR23","doi-asserted-by":"publisher","first-page":"6607","DOI":"10.1200\/JCO.2005.14.308","volume":"23","author":"K Dunleavy","year":"2005","unstructured":"Dunleavy K, White T, Grant N, Shovlin M, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Marti G, Janik J, Wilson WH: Phase 1 study of combination rituximab with apolizumab in relapsed\/refractory B-cell lymphoma and chronic lymphocytic leukemia. J Clin Oncol (Meeting Abstracts). 2005, 23: 6607-","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"878_CR24","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.4049\/jimmunol.147.12.4094","volume":"147","author":"GS Kansas","year":"1991","unstructured":"Kansas GS, Tedder TF: Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J Immunol. 1991, 147: 4094-4102.","journal-title":"J Immunol"},{"key":"878_CR25","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1084\/jem.172.5.1513","volume":"172","author":"W Mourad","year":"1990","unstructured":"Mourad W, Geha RS, Chatila T: Engagement of major histocompatibility complex class II molecules induces sustained, lymphocyte function-associated molecule 1-dependent cell adhesion. J Exp Med. 1990, 172: 1513-1516.","journal-title":"J Exp Med"},{"key":"878_CR26","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1084\/jem.20040119","volume":"199","author":"J Uchida","year":"2004","unstructured":"Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF: The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004, 199: 1659-1669.","journal-title":"J Exp Med"},{"key":"878_CR27","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.4049\/jimmunol.0713732","volume":"182","author":"M Leidi","year":"2009","unstructured":"Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, Roncalli M, Palumbo GA, Introna M, Golay J: M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol. 2009, 182: 4415-4422.","journal-title":"J Immunol"},{"key":"878_CR28","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1182\/blood-2009-10-249532","volume":"114","author":"M Introna","year":"2009","unstructured":"Introna M, Golay J: Complement in antibody therapy: friend or foe?. Blood. 2009, 114: 5247-5248.","journal-title":"Blood"},{"key":"878_CR29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000, 6: 443-446.","journal-title":"Nat Med"},{"key":"878_CR30","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1182\/blood.V99.3.754","volume":"99","author":"G Cartron","year":"2002","unstructured":"Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002, 99: 754-758.","journal-title":"Blood"},{"key":"878_CR31","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1200\/JCO.2007.14.8957","volume":"26","author":"A Musolino","year":"2008","unstructured":"Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2\/neu-positive metastatic breast cancer. J Clin Oncol. 2008, 26: 1789-1796.","journal-title":"J Clin Oncol"},{"key":"878_CR32","doi-asserted-by":"crossref","unstructured":"Larbouret C, Robert B, Bascoul-Mollevi C, Penault-Llorca F, Ho-Pun-Cheung A, Morisseau S, Navarro-Teulon I, Mach JP, Pelegrin A, Azria D: Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann Oncol. 21: 98-103.","DOI":"10.1093\/annonc\/mdp496"},{"key":"878_CR33","first-page":"141","volume":"252","author":"S Bondada","year":"2000","unstructured":"Bondada S, Bikah G, Robertson DA, Sen G: Role of CD5 in growth regulation of B-1 cells. Curr Top Microbiol Immunol. 2000, 252: 141-149.","journal-title":"Curr Top Microbiol Immunol"},{"key":"878_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.med.57.121304.131306","volume":"57","author":"J Folkman","year":"2006","unstructured":"Folkman J: Angiogenesis. Annu Rev Med. 2006, 57: 1-18.","journal-title":"Annu Rev Med"},{"key":"878_CR35","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0093-7754(03)00252-5","volume":"30","author":"M Dechant","year":"2003","unstructured":"Dechant M, Bruenke J, Valerius T: HLA class II antibodies in the treatment of hematologic malignancies. Semin Oncol. 2003, 30: 465-475.","journal-title":"Semin Oncol"},{"key":"878_CR36","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1002\/cncr.23890","volume":"113","author":"JP Leonard","year":"2008","unstructured":"Leonard JP, Schuster SJ, Emmanouilides C, Couture F, Teoh N, Wegener WA, Coleman M, Goldenberg DM: Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer. 2008, 113: 2714-2723.","journal-title":"Cancer"},{"key":"878_CR37","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1182\/blood-2002-07-1952","volume":"101","author":"S Faderl","year":"2003","unstructured":"Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B: Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003, 101: 3413-3415.","journal-title":"Blood"},{"key":"878_CR38","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1080\/10428190412331286096","volume":"45","author":"C Nabhan","year":"2004","unstructured":"Nabhan C, Patton D, Gordon LI, Riley MB, Kuzel T, Tallman MS, Rosen ST: A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and\/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2004, 45: 2269-2273.","journal-title":"Leuk Lymphoma"},{"key":"878_CR39","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1158\/1078-0432.CCR-05-1682","volume":"12","author":"JR Tonra","year":"2006","unstructured":"Tonra JR, Deevi DS, Corcoran E, Li H, Wang S, Carrick FE, Hicklin DJ: Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res. 2006, 12: 2197-2207.","journal-title":"Clin Cancer Res"},{"key":"878_CR40","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1158\/1078-0432.CCR-06-2302","volume":"13","author":"C Larbouret","year":"2007","unstructured":"Larbouret C, Robert B, Navarro-Teulon I, Thezenas S, Ladjemi MZ, Morisseau S, Campigna E, Bibeau F, Mach JP, Pelegrin A, Azria D: In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res. 2007, 13: 3356-3362.","journal-title":"Clin Cancer Res"},{"key":"878_CR41","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.leukres.2005.04.017","volume":"29","author":"S Loisel","year":"2005","unstructured":"Loisel S, Ster KL, Quintin-Roue I, Pers JO, Bordron A, Youinou P, Berthou C: Establishment of a novel human B-CLL-like xenograft model in nude mouse. Leuk Res. 2005, 29: 1347-1352.","journal-title":"Leuk Res"},{"key":"878_CR42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1046\/j.1432-1327.1999.00273.x","volume":"261","author":"A Rickers","year":"1999","unstructured":"Rickers A, Peters N, Badock V, Beyaert R, Vandenabeele P, Dorken B, Bommert K: Cleavage of transcription factor SP1 by caspases during anti-IgM-induced B-cell apoptosis. Eur J Biochem. 1999, 261: 269-274.","journal-title":"Eur J Biochem"},{"key":"878_CR43","first-page":"1784","volume":"45","author":"AO Schaffland","year":"2004","unstructured":"Schaffland AO, Buchegger F, Kosinski M, Antonescu C, Paschoud C, Grannavel C, Pellikka R, Delaloye AB: 131I-rituximab: relationship between immunoreactivity and specific activity. J Nucl Med. 2004, 45: 1784-1790.","journal-title":"J Nucl Med"},{"key":"878_CR44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0022-1759(84)90435-6","volume":"72","author":"T Lindmo","year":"1984","unstructured":"Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA: Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984, 72: 77-89.","journal-title":"J Immunol Methods"},{"key":"878_CR45","first-page":"176","volume":"91","author":"J Golay","year":"2006","unstructured":"Golay J, Cittera E, Di Gaetano N, Manganini M, Mosca M, Nebuloni M, van Rooijen N, Vago L, Introna M: The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica. 2006, 91: 176-183.","journal-title":"Haematologica"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-4598-10-42.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T12:46:32Z","timestamp":1686055592000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/1476-4598-10-42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,19]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["878"],"URL":"https:\/\/doi.org\/10.1186\/1476-4598-10-42","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,19]]},"assertion":[{"value":"10 September 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"42"}}